Investing in groundbreaking European biotech innovation
Biovance Capital is the leading life sciences investor in Portugal through Biovance Capital Fund I, a € 60 million venture capital fund backed by the European Investment Fund and the European Commission through the Portugal Tech and InvestEU programmes, the largest Portuguese pharmaceutical company BIAL, the national promotional bank Banco Português de Fomento, private investors such as Caixa Capital, Ageas Pensões, Fundo de Pensões EDP, in addition to other private investors from the USA and Europe. The fund invests in seed and Series A rounds of drug-developing companies across Europe, with a special focus on Southern Europe.. The fund invests in seed and Series A rounds for companies that are developing innovative medicines throughout Europe, with a special focus on Southern Europe.
